A Study of LY2623091 in Participants With High Blood Pressure
Status: | Completed |
---|---|
Conditions: | High Blood Pressure (Hypertension) |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - 80 |
Updated: | 2/7/2015 |
Start Date: | August 2014 |
End Date: | August 2015 |
Contact: | There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or |
Phone: | 1-317-615-4559 |
A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension
The main purpose of this study is to evaluate the safety and effectiveness of the study drug
known as LY2623091 in participants with high blood pressure.
known as LY2623091 in participants with high blood pressure.
Inclusion Criteria:
- Have a history of hypertension.
- If participants are naïve to treatment of hypertension, or have not been treated with
any antihypertensive medications within the 30 days immediately prior to screening:
- Have seated SBP of ≥140 and <170 millimeters of mercury (mmHg) at screening and
at the end of the lead-in period.
- If participants are currently being treated for hypertension:
- Are taking a stable dose of 1 or 2 antihypertensive medications for at least the
previous 30 days. A combination antihypertensive medication from 2 classes is
considered as 2 antihypertensive medications.
- Are willing to discontinue the antihypertensive medications during the study.
- Have seated SBP of ≥140 and <170 mmHg at the end of the lead-in period.
- Have a body mass index (BMI) ≥18.5 and <40 kilograms/m^2.
Exclusion Criteria:
- Have a history of severe hypertension (defined as SBP ≥180 mmHg and/or DBP ≥120
mmHg), secondary hypertension, symptomatic postural hypotension, or hospitalization
due to hypertension.
- Have SBP ≥180 mmHg and/or DBP ≥110 mmHg at screening, lead-in period, or
randomization.
- Have a history of hospitalization due to hyperkalemia, or history of drug
discontinuation due to elevated serum potassium levels.
- Have a serum potassium ≤3.5 or >5.0 millimoles per liter (mmol/L).
- Have an estimated glomerular filtration rate (eGFR) <50 milliliters/minute/1.73 m^2.
We found this trial at
33
sites
Site Overview Avail Clinical Research is a renowned and experienced clinical research site conducting Phase...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials